BRKRHealthcare · Medical DevicesThe 13 Wall Street analysts covering Bruker Corp. hold a median 12-month price target of $65 — +1.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bruker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (58): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | JP Morgan | Downgrade | Neutral | $60 |
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $60 → $62 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $58 → $70 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $70 → $72 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | $60 → $80 |
| 9 Sept 2026 | UBS | Maintains | Neutral | $45 → $65 |
| 9 Sept 2026 | UBS | Maintains | Neutral | — |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $60 → $53 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $44 → $60 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | $60 → $70 |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 8 June 2026 | JP Morgan | Maintains | Overweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BRKR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Bruker Corp. returned +58.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 46% of US stocks
Cheaper than 26% of US stocks
Cheaper than 16% of US stocks
Higher than 41% of US stocks
Higher than 43% of US stocks
Higher than 61% of US stocks
Higher than 64% of US stocks
Higher than 27% of US stocks
Higher than 41% of US stocks
Higher than 66% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bruker Corp. has a market value of $8.6B and an enterprise value of $10.2B.
Revenue in the twelve months to 30 June 2026: $3.5B. The latest quarter grew 5.2% year on year.
Net income over the same four quarters: −$64.5M, a −1.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.70.
Free cash flow in the twelve months to 30 June 2026: $64.5M.
Bruker Corp. spent $54.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 74.9×; forward P/E: 23.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.35%, paying out 38% of earnings.
Bruker Corp. employs 11,085 people — $316K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bruker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Bruker Corporation’s Q3 2026 earnings call, held November 4, 2026. The excerpt lists company executives and participating analysts but provides no discussion of results or guidance.
Why it matters — The transcript is a source for BRKR watchers, but this excerpt contains no substantive financial or operating details to assess.
Bruker reported third-quarter 2026 revenue growth of 1.6% to $874 million. Non-GAAP earnings per share increased 24.4% year over year to $0.56, supported by cost-saving actions and favorable product mix that contributed to margin expansion.
Why it matters — The results highlight revenue growth and improved non-GAAP earnings per share for BRKR, alongside the factors supporting margin expansion.
The article notes that Bruker’s revenue and EPS reflect its performance in the quarter ended September 2026, and suggests comparing key metrics with Wall Street estimates and year-ago figures.
Why it matters — Those comparisons offer BRKR watchers additional context for assessing the company’s quarterly performance.
U.S. stocks were higher on Wednesday, with the Dow Jones gaining around 1,100 points. The headline lists Bruker among stocks moving higher.
Why it matters — BRKR watchers may note that the headline reports Bruker shares rose during Wednesday’s broader market advance.
Bruker reported quarterly earnings of $0.56 per share, above the Zacks Consensus Estimate of $0.42. Earnings were $0.45 per share in the year-ago quarter.
Why it matters — The earnings beat and year-over-year comparison offer BRKR watchers an update on the company’s quarterly results.
The 13 Wall Street analysts covering Bruker Corp. have a median 12-month price target of $65, with estimates ranging from $50 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Bruker Corp., 6 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bruker Corp. 90 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Bruker Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +1.0% from the last close, and Ticker Nerd's factor model ranks Bruker Corp. 90 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bruker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $80 over the next 12 months.
Bruker Corp. returned +58.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "Bruker Corporation (BRKR) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Bruker Corporation’s Q3 2026 earnings call, held November 4, 2026. The excerpt lists company executives and participating analysts but provides no discussion of results or guidance.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications. The company develops, manufactures, and distributes high-performance tools used to study matter at microscopic, molecular, and cellular levels, supporting research and testing across academic, clinical, industrial, and government settings. Its product portfolio includes magnetic resonance, mass spectrometry, X-ray, microscopy, metrology, chromatography, and molecular spectroscopy systems, along with specialized diagnostic and microbiology solutions. Bruker serves customers in biopharmaceuticals, in-vitro diagnostics, nanotechnology, semiconductor process control, and applied markets, making it an important supplier of advanced measurement and detection technologies in the global scientific equipment market.
CEO Dr. Frank H. Laukien Ph.D. · 11,085 employees · United States · https://www.bruker.com
